Investor's Business Daily on MSN

Stock market today: Dow, Nasdaq struggle; these biopharma names make giant moves (live coverage)

The Dow Jones Industrial Average and other major indexes fell Monday afternoon as investors sold holdings in this ...

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Shares of Ultragenyx and Mereo BioPharma were rocked by disappointing late-stage trial results of their brittle-bone disease treatment. It's looking like a poor end to 2025 for investors in two ...

Long-Term Stock Portfolio: 10 Best Stocks for the Next Decade

On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ...

Mereo BioPharma stock plummets after failed Phase 3 trials

Investing.com -- Mereo BioPharma Group plc (NASDAQ:MREO) stock plunged 90.3% on Monday after the company announced that its Phase 3 clinical trials for setrusumab in Osteogenesis Imperfecta failed to ...
TipRanks on MSN

Mereo Biopharma updates setrusumab trials and cost controls

Mereo Biopharma Group Plc ( ($MREO) ) has shared an announcement. On December 29, 2025, Mereo BioPharma reported that its Phase 3 ORBIT and COSMIC ...

Ultragenyx Pharmaceutical, Mereo BioPharma Bone Disorder Treatment Doesn't Meet Trial Endpoints

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled 43.7% to $19.26 in pre-market trading after the company and its partner ...